相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia
Sebastien Gallien et al.
AIDS (2011)
Analysis of Low-Frequency Mutations Associated with Drug Resistance to Raltegravir before Antiretroviral Treatment
Jia Liu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy
Benjamin Young et al.
ANTIVIRAL THERAPY (2011)
Antiretroviral Drug Resistance in HIV-1-Infected Patients Experiencing Persistent Low-Level Viremia During First-Line Therapy
Babafemi Taiwo et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study
Linda Wittkop et al.
LANCET INFECTIOUS DISEASES (2011)
Self-report of current and prior antiretroviral drug use in comparison to the medical record among HIV-infected patients receiving primary HIV care
Emily Suzanne Brouwer et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: Potential role for an unexpected drug interaction
Massimiliano Fabbiani et al.
PHARMACOLOGICAL RESEARCH (2011)
High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors
Charlotte Charpentier et al.
AIDS (2010)
Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses
Jeffrey L. Lennox et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Lack of correlation between three commercial platforms for the evaluation of human immunodeficiency virus type 1 (HIV-1) viral load at the clinically critical lower limit of quantification
Celine S. Yan et al.
JOURNAL OF CLINICAL VIROLOGY (2010)
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment
Kimberly Y. Smith et al.
AIDS (2009)
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis
Anthony M. Mills et al.
AIDS (2009)
Abacavir-Lamivudine versus Tenofovir-Emtricitabine for Initial HIV-1 Therapy
Paul E. Sax et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
Roberto Ortiz et al.
AIDS (2008)
Antiretroviral drug resistance testing in adult HIV-1 infection:: 2008 recommendations of an International AIDS Society-USA panel
Martin S. Hirsch et al.
CLINICAL INFECTIOUS DISEASES (2008)
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and erntricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study
Jean-Michel Molina et al.
LANCET (2008)
Class-sparing regimens for initial treatment of HIV-1 infection
Sharon A. Riddler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Rapid and durable Antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection - Results of a 48-week controlled study
Martin Markowitz et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2007)
The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART
F van Leth et al.
AIDS (2005)
Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG Adherence Instruments
MA Chesney et al.
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV (2000)
分享论文
